Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1984-5-17
pubmed:abstractText
The effect of the imidazolidine Sgd 101/75 (2-[2-methylindazol-4-imino]-imidazolidine HCl) on blood pressure, as well as its alpha-adrenoceptor agonist activity and affinity for these receptors, were examined in various animal preparations. After both intravenous administration to conscious spontaneously hypertensive rats and intravenous injection or infusion via the vertebral artery in chloralose-anaesthetized cats, Sgd 101/75 (1-10 mg kg-1) elicited pressor responses. Intracisternal application of Sgd 101/75 (1 mg kg-1) to chloralose-anaesthetized cats did not affect blood pressure. In the pithed rat and pithed cat the vasopressor responses to i.v. Sgd 101/75 were effectively antagonized by prazosin (0.1-1.0 mg kg-1, i.v.) but much less by yohimbine (1 mg kg-1, i.v.). Sgd 101/75 proved a less potent and less selective displacing agent of [3H]-clonidine- and [3H]-prazosin-binding in rat brain membranes than clonidine. The results suggest that Sgd 101/75 is a selective alpha 1-adrenoceptor agonist, devoid of any centrally or peripherally mediated hypotensive activity; this is probably caused by the low capacity of Sgd 101/75 for stimulating alpha 2-adrenoceptors.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-13783713, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-14907713, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-17827, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-18248, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-20542, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-20591, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-228207, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-25484, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-5275866, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6111465, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6113530, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6117656, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6121597, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6122689, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6125586, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6175852, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6184552, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6247167, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6282885, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-6284763, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-7724, http://linkedlifedata.com/resource/pubmed/commentcorrection/6142740-921415
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
81
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
255-62
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Sgd 101/75: cardiovascular effects in various animal preparations; interactions with vascular postjunctional alpha 1- and alpha 2-adrenoceptors.
pubmed:publicationType
Journal Article